Cue Biopharma Expands Pipeline with Exclusive License from Ascendant Health Sciences Ltd. for Clinical-Stage Dual-Mechanism Anti-IgE Antibody

Stock Information for Cue Biopharma Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Cue Biopharma Inc.

Cue Biopharma Announces $30 Million Private Placement
Cue Biopharma Names Shao-Lee Lin M.D., Ph.D., CEO, President and Board Director to Lead Continued Growth and Transformation into a Clinical-Stage Company
Cue Biopharma Announces 1-for-30 Reverse Stock Split
Cue Biopharma to Present New Preclinical Data on Lead Autoimmune and Inflammatory Disease Candidate CUE-401 at IMMUNOLOGY2026
Cue Biopharma to Receive $7.5 Million Preclinical Milestone Payment from Boehringer Ingelheim Collaboration and License Agreement
Cue Biopharma Announces CEO Transition
Cue Biopharma to Host Virtual R&D Day Event on April 7, 2026
Cue Biopharma Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.